| AC220 |
| 1-(5-(tert-Butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea |
| (CAS 950769-58-1) |
 |
| Description： |
Quizartinib (AC220) is a small molecule receptor tyrosine kinase inhibitor that is currently under development by Ambit Biosciences for the treatment of acute myeloid leukaemia. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene.
Flt3 mutations are among the most common mutations in acute myeloid leukaemia due to internal tandem duplication of Flt3. The presence of this mutation is a marker of adverse outcome. |
| Product No. |
KT00032 |
| Product Name |
AC220 |
| Synonyms |
Quizartinib |
| Formal Name |
1-(5-(tert-Butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea |
| CAS Number |
950769-58-1 |
| Molecular Formula |
C29H32N6O4S |
| Formula Weight |
560.67 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
1 year |
| Storage |
-20℃ |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
AMG 925
Amuvatinib
AST 487
ENMD-2076
ENMD-2076 Tartrate
G-749
KW-2449
SB1317 |
|
